BioSpace News Archive

Biotech Beach

Arcutis, Inc. Founded to Address Gap in Immuno-Dermatology Drug Development

Arcutis, Inc., a privately held immuno-dermatology drug development company, was formed in 2016 to address significant unmet needs in dermatology.

April 24, 2019
·
4 min read
Business

Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors

Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy for chronic pain, is pleased to announce the addition of Edward J. Minskoff to its board of directors.

April 24, 2019
·
2 min read
BioCapital

HealthWell Foundation Opens New Amyloidosis Fund to Assist Patients with Treatment Costs - April 23, 2019

The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide copayment and premium assistance to patients living with amyloidosis.

April 24, 2019
·
3 min read
Drug Development

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

April 24, 2019
·
6 min read
FDA

FDA gives AbbVie’s Skyrizi a Thumbs-Up for Plaque Psoriasis

Plaque psoriasis is the most common type of psoriasis, caused by overproduction of skin cells. This causes inflamed, red lesions called plaques.

April 24, 2019
·
3 min read
·
Mark Terry
Business

Accenture’s New Science Report: An Interview With Stuart Henderson

Accenture recently published a new report, “New Science: Biopharma’s New Growth Machine.” In it, the report attempts to evaluate the last 20 years of trends in biopharma and use that data to develop projections for the future of the industry.

April 24, 2019
·
6 min read
·
Mark Terry
FDA

Biom’up granted FDA IDE approval for HEMOSNOW(TM)

Biom’up announced that the U.S. Food and Drug Administration approved the IDE application for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate developed by the Company for managing minimal and mild levels of bleeding during surgical procedures.

April 24, 2019
·
4 min read
Business

Academic entrepreneur Brian Bellhouse celebrated with naming of new building

Turf cutting for the Bellhouse Building to be performed by Lord & Lady Drayson

April 24, 2019
·
3 min read
Deals

Retrophin to Report First Quarter 2019 Financial Results

Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.

April 24, 2019
·
1 min read
Genetown

Fulcrum Therapeutics Licenses Failed GSK Drug for Possible Muscular Dystrophy Indication

Cambridge, Mass.-based Fulcrum Therapeutics just acquired a worldwide license with GlaxoSmithKline (GSK) to develop and commercialize losmapimod.

April 24, 2019
·
2 min read
·
Mark Terry